PC945, a potent, long-acting antifungal triazole, possesses activity against a broad range of both azole-susceptible and azole-resistant strains of Aspergillus fumigatus . PC945 is also a potent, tightly binding inhibitor of A. fumigatus sterol 14α-demethylase activity, CYP51A and CYP51B , with IC 50 s of 0.23 μM and 0.22 μM, respectively
In Vitro
PC945 is a triazole antifungal designed for administration via inhalation. PC945 exhibits the most potent antifungal activity on azole-susceptible strain NCPF2010 with the MIC value of 0.063 µg/mL. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PC945 (0.56-14 μg/mouse; intranasal; daily for 7 days) substantially inhibits the incidence of rolling behavior . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Specific-pathogen-free A/J mice (male, 5 weeks old, pulmonary Aspergillus infection) Dosage: 0.56, 2.8, 14 μg/mouse (intranasal application of 0.016-, 0.08-, and 0.4-mg/ml suspensions, respectively) Administration: Intranasal; daily for 7 days Result: Substantially inhibited the incidence of rolling behavior.
